WRD is interested in establishing alliances to develop and access:
Mechanisms, biomarkers, and screening approaches related to target organ toxicity
Cardiovascular safety
Liver injury
Hypersensitivity
Nephrotoxicity — esp., glomerular
Skeletal and cardiac muscle toxicity
Ocular safety
Screening for abuse potential
Biotherapeutics
Immunogenicity and other safety relevant assays
Deeper knowledge of targets and pathways
Knock-in, knock-out technologies
Humanized animal models
Novel technologies and increased throughput for target localization studies
Safety Biomarker Technologies
Platforms; multiplex; analytical approaches; validated reagents
Not actively seeking partnering opportunities in:
Genetox Screening
hERG related assays
In vitro screening models without significant validation
In silico approaches without experimental validation